The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-Positive Breast Cancer on Adjuvant Aromatase Inhibitor Therapy: Meta-Analysis

    August 2019 in “ Clinical breast cancer ”
    Radiša Pavlović, Slobodan M. Janković, Jasmina Milovanović … Miloš Milosavljević
    Studysummary This meta-analysis found that in postmenopausal women with a history of breast cancer, 8 weeks of vaginal estrogen therapy while on aromatase inhibitors did not result in systemic absorption of sex hormones, suggesting potential safety for treating vulvovaginal atrophy in this context.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on clinical-breast-cancer.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors The Journal of Clinical Endocrinology and Metabolism · 2018

    Related research 1

    1. Aromatase-Independent Testosterone Conversion Into Estrogenic Steroids Is Inhibited by a 5α-Reductase Inhibitor The Journal of Steroid Biochemistry and Molecular Biology · 2005